Artrya Limited (ASX:AYA), a medical technology company commercialising its Salix® AI-powered cloud platform for the assessment and management of coronary artery disease, has disclosed details of its 2026 Annual General Meeting scheduled for Friday, 13 November 2026 at 11.30am AWST, to be held at the company's offices at 1257 Hay Street, West Perth, Western Australia.
Key Points
- The 2026 AGM will be held on Friday, 13 November 2026 at 11.30am AWST (2.30pm AEDT) at Artrya's West Perth offices.
- A webinar option is available for shareholders unable to attend in person, though it will be in listen-only mode with no voting or question capability.
- Written questions from shareholders must be submitted prior to 11.30am AWST on Wednesday, 11 November 2026.
- Artrya describes itself as a medical technology company commercialising the Salix® AI-powered cloud platform for real-time, point-of-care coronary artery disease assessment and management.
2026 Annual General Meeting Details
Artrya Limited disclosed that its 2026 Annual General Meeting will be held at the company's offices at 1257 Hay Street, West Perth, Western Australia on Friday, 13 November 2026 commencing at 11.30am Australian Western Standard Time. The company released the notice as a reminder to shareholders of the upcoming meeting date and location. The filing was authorised for release by the Company Secretary of Artrya Limited. No agenda items or resolutions were detailed within this particular filing.
Webinar Access for Remote Shareholders
Artrya has made a webinar available for shareholders who are unable to attend the AGM in person. The webinar will begin at 11.30am AWST, equivalent to 2.30pm Australian Eastern Daylight Time, on 13 November 2026. The filing states that the webinar will not be interactive — shareholders attending via the webinar will be in listen-only mode and will be unable to cast votes on any resolution or raise questions during the meeting. Shareholders wishing to attend the webinar were directed to pre-register using a link provided in the filing.
Written Question Submission Deadline
Shareholders who wish to submit questions ahead of the 2026 AGM were advised by the company to do so in writing prior to 11.30am AWST on Wednesday, 11 November 2026. The filing does not specify the format or scope of questions that may be submitted. Artrya describes its core business as the commercialisation of the Salix® AI-powered cloud platform, which is designed for real-time, point-of-care assessment and management of coronary artery disease across global markets.



Please wait processing your request...